Prognostic factors for stage I ovarian carcinoma.

TitlePrognostic factors for stage I ovarian carcinoma.
Publication TypeJournal Article
Year of Publication2010
AuthorsSeidman JD, Yemelyanova AV, Khedmati F, Bidus MA, Dainty L, Boice CR, Cosin JA
JournalInt J Gynecol Pathol
Volume29
Issue1
Pagination1-7
Date Published2010 Jan
ISSN1538-7151
KeywordsAntineoplastic Agents, Combined Modality Therapy, Female, Gynecologic Surgical Procedures, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Prognosis
Abstract

Stage I ovarian carcinoma is relatively uncommon, and data on prognostic factors are conflicting. The clinical and pathologic features of 51 International Federation of Gynecology and Obstetrics stage I ovarian carcinomas were analyzed. There were 22 stage IA, 1 stage IB, and 28 stage IC cases. The mean follow-up was 6.1 years. The 5-year and 10-year disease-specific survival rates for the entire cohort were 92% and 78%, respectively. Among 51 patients, there were 6 tumor deaths, and 1 patient died of unrelated causes. All patients who died of disease were stage IC. Significant adverse prognostic factors were serous histology [relative risk (RR) 5.4, 95% confidence interval (CI) 1.3-22.0] and stage IC (RR 1.3, 95% CI 1.1-1.5). Among factors associated with stage IC, only positive washings or ascites affected survival (RR 9.25, 95% CI 1.9-44.4). The 5-year survival rates for stages IA and IC were 100% and 83%, respectively (P<0.025, log rank test). For comprehensively staged patients, the 5-year survival rate was 96% as compared with 72% for all others (P<0.025, log rank test). Tumor rupture, surface involvement, histologic grade and clear cell histology were not of adverse prognostic significance. Serous histology and positive washings or ascites are adverse prognostic factors in stage I. The prognostic importance of tumor grade, rupture, surface involvement and clear cell histology remains unclear. Patients who are International Federation of Gynecology and Obstetrics stage I on the basis of comprehensive surgical staging have an excellent prognosis.

DOI10.1097/PGP.0b013e3181af2372
Alternate JournalInt J Gynecol Pathol
PubMed ID19952945
Related Faculty: 
Anna Yemelyanova, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700